OncoSec Medical (ONCS) Faces Nasdaq Delisting
- June 23rd, 2023
- 234 views
On June 15, 2023, the Chapter 7 bankruptcy trustee for OncoSec Medical Incorporated (Nasdaq: ONCS) received a letter from Nasdaq's Listing Qualifications Department, as disclosed in a regulatory filing with the SEC.
The letter informed both the trustee and the company that Nasdaq has decided to delist OncoSec's securities based on several factors, including the Chapter 7 filing, concerns regarding existing securities holders' equity interest, and non-compliance with listing requirements. It further stated that the trading of the company's common stock will be suspended on June 26, 2023, and the securities will be removed from listing and registration on Nasdaq.
OncoSec Medical Incorporated stated that it does not intend to challenge the determination made by Nasdaq's Listing Qualifications Department. As a result, the company expects that its common stock will be suspended from trading at the start of business on June 26, 2023, and subsequently delisted from Nasdaq.
Despite the impending delisting, $ONCS is currently experiencing pre-market trading at $0.43, representing an increase of $0.22 (+104.57%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login